592 related articles for article (PubMed ID: 25862300)
1. An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures.
Pereira RC; Silva AN; Souza MC; Silva MV; Neves PP; Silva AA; Matos DD; Herrera MA; Yamamura AM; Freire MS; Gaspar LP; Caride E
Vaccine; 2015 Aug; 33(35):4261-8. PubMed ID: 25862300
[TBL] [Abstract][Full Text] [Related]
2. An inactivated cell-culture vaccine against yellow fever.
Monath TP; Fowler E; Johnson CT; Balser J; Morin MJ; Sisti M; Trent DW
N Engl J Med; 2011 Apr; 364(14):1326-33. PubMed ID: 21470010
[TBL] [Abstract][Full Text] [Related]
3. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development.
Gaspar LP; Mendes YS; Yamamura AM; Almeida LF; Caride E; Gonçalves RB; Silva JL; Oliveira AC; Galler R; Freire MS
J Virol Methods; 2008 Jun; 150(1-2):57-62. PubMed ID: 18420285
[TBL] [Abstract][Full Text] [Related]
4. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity.
Monath TP; Lee CK; Julander JG; Brown A; Beasley DW; Watts DM; Hayman E; Guertin P; Makowiecki J; Crowell J; Levesque P; Bowick GC; Morin M; Fowler E; Trent DW
Vaccine; 2010 May; 28(22):3827-40. PubMed ID: 20347059
[TBL] [Abstract][Full Text] [Related]
5. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.
Julander JG; Trent DW; Monath TP
Vaccine; 2011 Aug; 29(35):6008-16. PubMed ID: 21718741
[TBL] [Abstract][Full Text] [Related]
6. Production of yellow fever 17DD vaccine virus in primary culture of chicken embryo fibroblasts: yields, thermo and genetic stability, attenuation and immunogenicity.
Freire MS; Mann GF; Marchevsky RS; Yamamura AM; Almeida LF; Jabor AV; Malachias JM; Coutinho ES; Galler R
Vaccine; 2005 Mar; 23(19):2501-12. PubMed ID: 15752837
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak - Final Report.
Casey RM; Harris JB; Ahuka-Mundeke S; Dixon MG; Kizito GM; Nsele PM; Umutesi G; Laven J; Kosoy O; Paluku G; Gueye AS; Hyde TB; Ewetola R; Sheria GKM; Muyembe-Tamfum JJ; Staples JE
N Engl J Med; 2019 Aug; 381(5):444-454. PubMed ID: 29443626
[TBL] [Abstract][Full Text] [Related]
8. Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys.
Marchevsky RS; Freire MS; Coutinho ES; Galler R
Virology; 2003 Nov; 316(1):55-63. PubMed ID: 14599790
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
Collaborative Group for Studies with Yellow Fever Vaccine
Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925
[TBL] [Abstract][Full Text] [Related]
10. Purification of yellow fever virus produced in Vero cells for inactivated vaccine manufacture.
Pato TP; Souza MCO; Mattos DA; Caride E; Ferreira DF; Gaspar LP; Freire MS; Castilho LR
Vaccine; 2019 May; 37(24):3214-3220. PubMed ID: 31047674
[TBL] [Abstract][Full Text] [Related]
11. Booster dose after 10 years is recommended following 17DD-YF primary vaccination.
Campi-Azevedo AC; Costa-Pereira C; Antonelli LR; Fonseca CT; Teixeira-Carvalho A; Villela-Rezende G; Santos RA; Batista MA; Campos FM; Pacheco-Porto L; Melo Júnior OA; Hossell DM; Coelho-dos-Reis JG; Peruhype-Magalhães V; Costa-Silva MF; de Oliveira JG; Farias RH; Noronha TG; Lemos JA; von Doellinger Vdos R; Simões M; de Souza MM; Malaquias LC; Persi HR; Pereira JM; Martins JA; Dornelas-Ribeiro M; Vinhas Ade A; Alves TR; Maia Mde L; Freire Mda S; Martins Rde M; Homma A; Romano AP; Domingues CM; Tauil PL; Vasconcelos PF; Rios M; Caldas IR; Camacho LA; Martins-Filho OA
Hum Vaccin Immunother; 2016; 12(2):491-502. PubMed ID: 26360663
[TBL] [Abstract][Full Text] [Related]
12. Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination.
da Costa-Rocha IA; Machado KLLL; Campi-Azevedo AC; Teixeira-Carvalho A; Peruhype-Magalhães V; de Lima SMB; Miranda EH; Trindade GF; Casagrande TZ; Miyamoto ST; Deotti SC; Barbosa RVR; Rocha PCM; Serrano EV; Dinis VG; Gouvêa SA; Gavi MBRO; da Silva LB; Duque RH; Gianordoli APE; Bissoli MF; Gouvea MDPG; Pinto-Neto LFDS; Burian APN; Fantinato FFST; Pileggi GS; da Mota LMH; Valim V; Martins-Filho OA
Sci Rep; 2021 May; 11(1):10431. PubMed ID: 34001945
[TBL] [Abstract][Full Text] [Related]
13. 17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil.
Campi-Azevedo AC; Peruhype-Magalhāes V; Coelho-Dos-Reis JG; Antonelli LR; Costa-Pereira C; Speziali E; Reis LR; Lemos JA; Ribeiro JGL; Bastos Camacho LA; de Sousa Maia ML; Barbosa de Lima SM; Simões M; de Menezes Martins R; Homma A; Cota Malaquias LC; Tauil PL; Costa Vasconcelos PF; Martins Romano AP; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
Emerg Infect Dis; 2019 Aug; 25(8):1511-1521. PubMed ID: 31298654
[TBL] [Abstract][Full Text] [Related]
14. Plant-Produced Subunit Vaccine Candidates against Yellow Fever Induce Virus Neutralizing Antibodies and Confer Protection against Viral Challenge in Animal Models.
Tottey S; Shoji Y; Jones RM; Chichester JA; Green BJ; Musiychuk K; Si H; Manceva SD; Rhee A; Shamloul M; Norikane J; Guimarães RC; Caride E; Silva ANMR; Simões M; Neves PCC; Marchevsky R; Freire MS; Streatfield SJ; Yusibov V
Am J Trop Med Hyg; 2018 Feb; 98(2):420-431. PubMed ID: 29231157
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil.
Gonçalves AP; Almeida LT; Rezende IMd; Fradico JRB; Pereira LS; Ramalho DB; Pascoal Xavier MA; Calzavara Silva CE; Monath TP; LaBeaud AD; Drumond BP; Campi-Azevedo AC; Martins-Filho OA; Teixeira-Carvalho A; Alves PA;
Microbiol Spectr; 2024 May; 12(5):e0370323. PubMed ID: 38511952
[TBL] [Abstract][Full Text] [Related]
16. Heparin removal by ecteola-cellulose pre-treatment enables the use of plasma samples for accurate measurement of anti-Yellow fever virus neutralizing antibodies.
Campi-Azevedo AC; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Costa-Pereira C; Yamamura AY; Lima SMB; Simões M; Campos FMF; de Castro Zacche Tonini A; Lemos EM; Brum RC; de Noronha TG; Freire MS; Maia MLS; Camacho LAB; Rios M; Chancey C; Romano A; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
J Immunol Methods; 2017 Sep; 448():9-20. PubMed ID: 28514646
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil.
Galler R; Pugachev KV; Santos CL; Ocran SW; Jabor AV; Rodrigues SG; Marchevsky RS; Freire MS; Almeida LF; Cruz AC; Yamamura AM; Rocco IM; da Rosa ES; Souza LT; Vasconcelos PF; Guirakhoo F; Monath TP
Virology; 2001 Nov; 290(2):309-19. PubMed ID: 11883195
[TBL] [Abstract][Full Text] [Related]
18. Comparing immunogenicity and protective efficacy of the yellow fever 17D vaccine in mice.
Ma J; Boudewijns R; Sanchez-Felipe L; Mishra N; Vercruysse T; Buh Kum D; Thibaut HJ; Neyts J; Dallmeier K
Emerg Microbes Infect; 2021 Dec; 10(1):2279-2290. PubMed ID: 34792431
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial.
Camacho LA; Freire Mda S; Leal Mda L; Aguiar SG; Nascimento JP; Iguchi T; Lozana Jde A; Farias RH;
Rev Saude Publica; 2004 Oct; 38(5):671-8. PubMed ID: 15499438
[TBL] [Abstract][Full Text] [Related]
20. New approaches for the standardization and validation of a real-time qPCR assay using TaqMan probes for quantification of yellow fever virus on clinical samples with high quality parameters.
Fernandes-Monteiro AG; Trindade GF; Yamamura AM; Moreira OC; de Paula VS; Duarte AC; Britto C; Lima SM
Hum Vaccin Immunother; 2015; 11(7):1865-71. PubMed ID: 26011746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
